MEDIFAST INC (MED) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, MEDIFAST INC (NYSE: MED) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.26 (-0.16% 1D, market cap $137.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 146 tracked Consumer Staples issuers, MED ranks #78 in composite RQD confidence.
Within the Consumer Staples sector (Packaged Foods), MED carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -10.2%. By comparison, BYND (Beyond Meat Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $126.9M) and BGS (B&G Foods Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC 3.3%, cap $183.7M). Among the 5-stock peer group, MED leads on earnings multiple (N/A) while BGS leads on capital efficiency (3.3% ROIC).
Per MED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000910329), MEDIFAST INC generated $385.8M in revenue (-36.0% YoY), -$19.0M in net income, and $1.2M in free cash flow against $248.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0.3% FCF Margin ($1.2M FCF) & 71.3% Gross Margin
20D Institutional Volume Accumulation (±7% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While MED currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Staples with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.00) and Max Pain ($12.87) forces dealer call-delta covering toward $14.12.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MEDIFAST INC (MED) slipped -0.16% to $12.26, trading at 72% of its 52-week range ($9.22 – $13.45). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
Wellness company Medifast (NYSE:MED) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 19.4% year on year to $72.05 million. Guidance for next quarter’s revenue was better than expecte
Medifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline. Management attributed the pe
Medifast maintains a strong, cash-heavy balance sheet and trades near liquidation value. Read more on MED stock and why it is a Hold.
Shares of wellness company Medifast (NYSE:MED) jumped 6.2% in the afternoon session after the company, in a press release, reported third quarter results, with sales exceeding Wall Street's expectations. Medifast generat
Medifast stock inched 3.1% higher to US$12.49 on the first full trading day after its Q3 2026 report, a modest move for what was a far more dramatic income statement. The company posted a GAAP net loss of US$17.5m on US$
MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.
CEO Johnson targets Q4 profitability amid record coach productivity gains.
Moby summary of Medifast, Inc.'s Q3 2026 earnings call
Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was withi
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -36.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MED today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MED. Explore sector supply chains on /butterfly.
Across 146 tracked Consumer Staples securities in the Roarable RQD universe, MEDIFAST INC (MED) ranks #78 by composite RQD confidence (50/100, grade D) and #99 by equity capitalization ($137.1M). Within this direct 5-issuer industry benchmark cohort, MED leads on earnings valuation at N/A trailing P/E, while BGS leads on capital efficiency and profitability with 3.3% ROIC and 21.8% gross margin. MED currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MED
ACTIVE
MEDIFAST INC | D | 50/100 | — | 71.3% | -10.2% | -0.16% | $137.1M | Benchmark Subject |
| BYND Beyond Meat Inc. | E | 29/100 | — | — | -35.0% | +3.51% | $126.9M | /bynd-vs-med → |
| BGS B&G Foods Inc. | E | 28/100 | — | 21.8% | 3.3% | +9.71% | $183.7M | /bgs-vs-med → |
| OTLY Oatly Group AB | D | 45/100 | — | — | — | -6.54% | $255.3M | /otly-vs-med → |
| AFRI Forafric Global PLC | E | 24/100 | — | 10.4% | -16.5% | -0.08% | $340.6M | /afri-vs-med → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MEDIFAST INC (MED) reported GAAP revenue of $385.8M (-36.0% vs. FY2024 revenue of $602.5M , and -64.0% cumulative change since FY2023) , GAAP net income of -$19.0M, operating cash flow of $6.9M, and free cash flow of $1.2M (-92.7% YoY). On the balance sheet, MED closed FY2025 with $248.0M in total assets against $0 in total debt (Altman Z-Score: 4.71, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $385.8M | -$19.0M | $6.9M | $1.2M | $248.0M | — |
| FY2024 (FY) | 2024-12-31 | $602.5M | $2.0M | $24.5M | $17.0M | $284.2M | — |
| FY2023 (FY) | 2023-12-31 | $1.07B | $99.0M | $147.7M | $147.7M | — | — |
As of 2026-11-02, MEDIFAST INC (NYSE: MED) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.26 (-0.16% 1D, market cap $137.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 146 tracked Consumer Staples issuers, MED ranks #78 in composite RQD confidence.
Within the Consumer Staples sector (Packaged Foods), MED carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -10.2%. By comparison, BYND (Beyond Meat Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $126.9M) and BGS (B&G Foods Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC 3.3%, cap $183.7M). Among the 5-stock peer group, MED leads on earnings multiple (N/A) while BGS leads on capital efficiency (3.3% ROIC).
Per MED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000910329), MEDIFAST INC generated $385.8M in revenue (-36.0% YoY), -$19.0M in net income, and $1.2M in free cash flow against $248.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MED last traded at $12.26 (-0.16% on volume of 124,467 shares), positioning the stock +2.17% above its 50-day simple moving average ($12.00) and +8.30% above its 200-day simple moving average ($11.32). Across its 52-week range of $9.22 to $13.45, MED sits at the 71.9% percentile with a 14-day RSI of 56.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.0% ($11.40 to $13.12).
Why MED Stock slipped -0.16% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).